The Therapeutic Pipeline Program at the Michael J. Fox Foundation for Parkinson’s Research is focused on advancing the development of Parkinson's disease therapies and interventions along the pre-clinical and clinical path (i.e., both drug and non-pharmacological therapeutics, including gene therapy, biological, surgical and non-invasive approaches).
To that end, MJFF is inviting proposals for research with the potential for fundamentally altering disease course and/or significantly improving treatment of symptoms above and beyond current standards of care.
The program is open to industry and academic investigators proposing novel approaches or repositioning approved or clinically safe therapies from non-PD indications in three areas:
Applied Technologies as Treatments for Parkinson's — The use of innovative technologies (e.g., assistive devices, wearable technologies) is an emerging and rapidly developing area offering new treatment opportunities for those with PD. Proposals should focus on testing the efficacy of novel devices and technologies designed to address critical, poorly managed symptoms of Parkinson’s disease. The foundation is particularly interested in: proof-of-concept efficacy and/or feasibility studies from prototype or available devices and technologies; and analysis of existing clinical data sets from studies of applied technologies for evidence of clinical impact in people with PD.
Disease-Modifying Strategies — The goal of the proposed research should be to protect or restore degenerating and/or dysfunctional neurons affected in PD. Proposals may target any of the following (though investigators are not restricted to this list): alpha-synuclein; GBA; inflammation; LRRK2; mitochondrial function; protein folding.
Symptomatic Strategies — The goal of the proposed research should be to significantly improve treatment of symptoms above and beyond current standards of care. Proposals may aim to achieve any of the following: alleviate motor symptoms of PD; alleviate non-motor symptoms of PD; and/or reduce complications and side effects of current PD treatments
All proposals must have a well-defined plan for moving toward clinical utility for Parkinson's disease (PD) patients.
The foundation anticipates awarding one- to two-year grants of up to $500,000 for pre-clinical or applied technology programs, and one- to two-year grants of up to $2 million for clinical programs.
The foundation will host a funding opportunities informational webinar on Monday, April 1, at 12:00 ET. (Registration required.)
Pre-proposals are due April 19 at 5:00 p.m. ET. Full proposal invitations will be sent out the week of June 10, with full proposals due (by invite only) by 5:00 ET on July 19. The foundation anticipates making the award announcements in September and distributing the awards in October.
See the Michael J. Fox Foundation for Parkinson's Research website for program details, application instructions and templates, and access to the application portal.